JP2005511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511632A5
JP2005511632A5 JP2003545300A JP2003545300A JP2005511632A5 JP 2005511632 A5 JP2005511632 A5 JP 2005511632A5 JP 2003545300 A JP2003545300 A JP 2003545300A JP 2003545300 A JP2003545300 A JP 2003545300A JP 2005511632 A5 JP2005511632 A5 JP 2005511632A5
Authority
JP
Japan
Prior art keywords
receptor agonist
cannabinoid receptor
medicament
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2002/002108 external-priority patent/WO2003043619A1/en
Publication of JP2005511632A publication Critical patent/JP2005511632A/ja
Publication of JP2005511632A5 publication Critical patent/JP2005511632A5/ja
Pending legal-status Critical Current

Links

JP2003545300A 2001-11-23 2002-11-20 胃食道逆流疾患の治療のための新しい使用 Pending JP2005511632A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
JP2005511632A JP2005511632A (ja) 2005-04-28
JP2005511632A5 true JP2005511632A5 (cg-RX-API-DMAC7.html) 2006-01-12

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545300A Pending JP2005511632A (ja) 2001-11-23 2002-11-20 胃食道逆流疾患の治療のための新しい使用

Country Status (20)

Country Link
US (1) US7358245B2 (cg-RX-API-DMAC7.html)
EP (1) EP1453497A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005511632A (cg-RX-API-DMAC7.html)
KR (1) KR20050044582A (cg-RX-API-DMAC7.html)
CN (1) CN1610542A (cg-RX-API-DMAC7.html)
AR (1) AR037299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002353700A1 (cg-RX-API-DMAC7.html)
BR (1) BR0214319A (cg-RX-API-DMAC7.html)
CA (1) CA2466916A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0402080A3 (cg-RX-API-DMAC7.html)
IL (1) IL161748A0 (cg-RX-API-DMAC7.html)
IS (1) IS7272A (cg-RX-API-DMAC7.html)
MX (1) MXPA04004774A (cg-RX-API-DMAC7.html)
NO (1) NO20042613L (cg-RX-API-DMAC7.html)
NZ (1) NZ532844A (cg-RX-API-DMAC7.html)
PL (1) PL369402A1 (cg-RX-API-DMAC7.html)
RU (1) RU2280443C2 (cg-RX-API-DMAC7.html)
TW (1) TW200407110A (cg-RX-API-DMAC7.html)
WO (1) WO2003043619A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403785B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415851A (pt) * 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20110172305A1 (en) * 2007-10-02 2011-07-14 Ester Fride Endocannabinoids for Enhancing Growth and Development in Infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
KR100604742B1 (ko) * 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) * 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Similar Documents

Publication Publication Date Title
CN109549927A (zh) 固溶体组合物及其在心血管疾病中的用途
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
JP2011068669A (ja) Gerdの治療のためのmglur5アンタゴニストの使用
US20110237563A1 (en) Fast dissolving drug delivery systems
AU2011231645A1 (en) Fast dissolving drug delivery systems
WO2007070504A2 (en) Stable and palatable oral liquid sumatriptan compositions
EP4297868A1 (en) Use of aprepitant for treating alzheimer's disease
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JP2007512273A (ja) ベータ−3−アドレノセプター作用薬及びプロスタグランジン代謝に影響を及ぼす活性物質から成る医薬組成物
TWI419689B (zh) 用於治療薩羅霍症(Sialorrhoea)之醫藥組合物
US10682343B2 (en) Snoring treatment
JP2001520678A (ja) 睡眠無呼吸症候群の治療に有効な医薬の製造への特異的5ht▲下2▼レセプター拮抗薬の使用
RU2004114843A (ru) Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни
CA2544100A1 (en) Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
CN107073015B (zh) 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
JP5042625B2 (ja) 抗炎症剤として有用なα−アミノアミド誘導体
CA2464309A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
US20050154041A1 (en) Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
AU2007325972A1 (en) S-nitrosothiol compounds and related derivatives
EP3965823B1 (en) Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases
JPWO2006003910A1 (ja) メニエール病の予防および/または治療剤
CN102781437A (zh) 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
CN101291660A (zh) 恢复正常呼吸节律的基于s-亚硝基硫醇的复方药品
CN107496426A (zh) 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物